From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry has grown in recent years and by 2014 state bioscience firms employed just over 24,000 in nearly 1,300 business establishments. Four of the state’s five bioscience subsectors have contributed to its 2 percent overall employment gain since 2012, led by double-digit job growth in medical devices (up 11 percent). State academic institutions accounted for nearly $400 million in bioscience-related R&D expenditures in 2014 and NIH funding to these and other non-academic institutions totaled $150.6 million in 2015. Arizona inventors have had 1,751 patents issued in bioscience-related classes since 2012, primarily in medical and surgical devices but also in drugs and pharmaceuticals, microbiology and genetics, and in biochemistry. The state has seen a strong increase in venture capital invested in bioscience-related companies in recent years. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Chandler, Arizona —-The Arizona Bioindustry Association will honor Rowpar Pharmaceuticals, Inc, manufacturer of ClōSYS® oral health products, with an AZBio Fast Lane Award at the 2017 AZBio Awards.
Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress
CPP-1X/sul aims to prevent disease progression in patients with Familial Adenomatous Polyposis
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide
The TAUG-HD v1.0 describes how HD clinical data should be recorded in a standardized database to establish common best practices across the healthcare industry for the recording, reporting, and sharing of clinically relevant disease-specific metadata, research data, and patient information.
- The MedTech Conference 2017
- 09/25/2017 - 09/27/2017
- San Jose
- RESI Boston 2017
- Helping Cancer Caregivers in the Workplace
- Rocky Mountain Life Science Investor and Partnering Conference
- 10/02/2017 - 10/03/2017
- Telemedicine and Telehealth Service Provider Showcase
- 10/02/2017 - 10/03/2017